MannKind (MNKD) Q1 2026 earnings review
Top-Line Growth Masks Severe Profitability Reversal
MannKind's Q1 2026 highlights a company undergoing a sudden, costly transformation. Total revenue grew 15% YoY to $90.2M, driven entirely by the inorganic addition of the newly acquired Furoscix ($15.5M). However, the cost of this growth was punishing: operating expenses exploded, with SG&A up 116% as the company built out launch infrastructure for Furoscix and the potential Afrezza pediatric label. Consequently, MannKind's trajectory violently reversed from a reliable, non-GAAP profitable operation to a deep GAAP net loss of $16.6M. With Afrezza revenues decelerating sequentially, management must prove this heavy investment cycle will yield immediate returns following the upcoming critical summer PDUFA dates.
🐂 Bull Case
Furoscix generated $15.5M in its first full quarter under MannKind, driving total commercial sales up. Dispensed doses increased 64% YoY. If the ReadyFlow Autoinjector is approved in July, it represents a massive catalyst to scale growth.
With two major PDUFA dates within the next three months (Afrezza pediatric in May, Furoscix ReadyFlow in July), MannKind is positioned for significant regulatory and commercial tailwinds that could justify the current heavy OpEx spend.
🐻 Bear Case
The operational leverage built over 2025 has evaporated. SG&A spiked 116% and R&D jumped 56%. The resulting $16.6M net loss proves the scPharma acquisition and pediatric launch prep are draining cash rapidly.
Excluding Furoscix, organic commercial revenues actually declined. Afrezza grew only 3% YoY to $15.3M (and dropped significantly from Q3 2025's $18.5M), while V-Go continued its managed decline, dropping 23%.
⚖️ Verdict: ⚪
Neutral. The inorganic revenue growth and upcoming pipeline catalysts are highly promising, but the staggering 116% surge in SG&A expenses and the resulting plunge into unprofitability create substantial execution risk over the next 12 months.
Key Themes
Operating Expense Explosion Crushes Margins
The most glaring break in trend is the aggressive ramp in operating expenses. SG&A surged 116% YoY to $54.1M, vastly outpacing the 15% revenue growth. This was driven by the integration of scPharma (Furoscix promotion) and expanding field teams for the Afrezza pediatric launch. Furthermore, overall commercial gross margins declined because Furoscix carries a lower margin than Afrezza. This dual pressure reversed the company's profitability trajectory.
Furoscix Validates scPharma Acquisition
Furoscix immediately established itself as a co-lead commercial asset, generating $15.5M in Q1 and slightly edging out Afrezza ($15.3M). Management noted dispensed doses grew 64% YoY (comparing against scPharma's standalone Q1 2025). The upcoming July 2026 PDUFA date for the Furoscix ReadyFlow Autoinjector is critical—if approved, it allows an IV-equivalent diuretic dose in under 10 seconds, massively expanding the product's market appeal.
Afrezza Core Business is Decelerating
Despite management's optimism surrounding the pediatric label expansion, the adult Afrezza business is showing signs of fatigue. Q1 revenue of $15.3M represents anemic 3% YoY growth, and crucially, a sequential deceleration from Q2 2025 ($18.3M) and Q3 2025 ($18.5M). If the pediatric label (PDUFA May 29) is not approved or fails to gain immediate traction, the heavy SG&A investments tied to it will look severely misplaced.
Tyvaso DPI Royalties Remain the Stable Bedrock
Royalties from United Therapeutics' Tyvaso DPI continue to provide stable, high-margin funding, growing 9% YoY to $32.7M. However, Collaboration and Services revenue reversed, falling 20% YoY to $23.5M due to fewer units sold to UT. This highlights the volatility in the manufacturing side of the UT partnership, though the end-user demand (royalties) remains solid.
Accelerating Orphan Lung Development (MNKD-201 & MNKD-1501)
MannKind is pushing forward with its proprietary DPI technology. The Nintedanib DPI (MNKD-201) program for IPF completed Cohort 1 of Phase 1b and is accelerating into a Phase 2 trial (INFLO-2) in Q2 2026. Additionally, United Therapeutics paid $5M to accelerate the Ralinepag DPI (MNKD-1501) program. This expansion beyond diabetes and cardiorenal solidifies the pipeline but also explains the 56% surge in R&D costs.
Other KPIs
Decelerating. Cash reserves have dwindled significantly from the $198M reported in Q1 2025, and are down substantially from the $286M post-debt position in Q3 2025. While adequate for near-term operations, the heavy $16.6M quarterly GAAP net loss limits the company's operational runway without further financing if product launches stumble.
Accelerating dramatically by 99% YoY. This outpaces total commercial revenue growth, validating management's note that gross margins are being compressed by the inclusion of Furoscix (on-body infusor), which operates at a structurally lower margin profile than Afrezza.
Guidance
This is the most critical near-term milestone. The company has already preemptively spent millions expanding field-based teams for this event. Rejection or a delay would be catastrophic for the immediate operating leverage thesis.
Management views this as a vital lifecycle management tool to improve patient compliance and reduce cost of goods sold. A timely approval is required to improve the currently strained Furoscix gross margin profile.
Accelerating from previous timelines. Execution of this IPF trial represents the next step in validating the orphan lung disease pipeline.
Key Questions
Afrezza Sequential Decline
Afrezza revenues dropped back to $15.3M after running in the mid-$18M range during Q2 and Q3 2025. Is this purely Q1 seasonality/deductible resets, or is the adult core market losing momentum ahead of the pediatric launch?
Furoscix Margin Bridge
Furoscix clearly pressured commercial gross margins this quarter. If the ReadyFlow Autoinjector is approved in July, what is the exact cadence for phasing out the on-body infusor, and when will Furoscix gross margins approach parity with the endocrine business?
OpEx Run Rate Stabilization
SG&A reached an astonishing $54.1M this quarter. With the launch infrastructure now reportedly 'built out,' should investors consider this the new baseline run rate, or will these expenses scale down post-launch?
Collaboration Revenue Volatility
Collaboration revenues from UT fell 20% due to lower manufacturing unit sales. Does this represent an inventory destocking effect by UT, and should we expect a rebound in the back half of the year?